risk of glp 1 for weight loss GLP-1 drugs leave users low on key nutrients, study finds INFOGRAPHIC: The Hidden Risks of

Eli Lillys obesity pill was approved by the Food and Drug Administration on Wednesday, setting it up for fierce competition against Novo Nordisks new Wegovy pill as more people seek alternatives to GLP-1 injections

Ethical Statement This article is a narrative review of previously published studies and does not involve new data collection involving human or animal subjects

Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Insulin Glargine as Add-on to Metformin (With or Without Sulfonylureas) in Insulin-Naive Patients With Type 2 Diabetes (SUSTAIN 4): A Randomised, Open-Label, Parallel-Group, Multicentre, Multinational, Phase 3a Trial

PlexusDx serves patients across all BMI categories who meet clinical criteria for these medications

This is why most diet-only approaches see weight regain beginning within the first year, while GLP-1 medications extend the active loss phase to 18 to 24 months or longer

The broader category of weight loss peptides leverages these same GLP-1 pathways